<乌鸦传媒>Dear Blood Donors, You've Given Me the Gift of Life I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
<乌鸦传媒>FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
<乌鸦传媒>Finally, a 'New Standard' for Severe Aplastic Anemia After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
<乌鸦传媒>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<乌鸦传媒>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<乌鸦传媒>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<乌鸦传媒>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<乌鸦传媒>Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
<乌鸦传媒>Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<乌鸦传媒>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<乌鸦传媒>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<乌鸦传媒>R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<乌鸦传媒>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<乌鸦传媒>尾-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<乌鸦传媒>R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<乌鸦传媒>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<乌鸦传媒>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<乌鸦传媒>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<乌鸦传媒>Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
<乌鸦传媒>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<乌鸦传媒>Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<乌鸦传媒>Is Multiple Myeloma a Greater Threat to Black Patients? Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
<乌鸦传媒>A Gentler Standard for Acute Promyelocytic Leukemia in Kids ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
<乌鸦传媒>Vaccinated Blood Cancer Patients Still at Risk for Severe COVID-19 Those with hematologic malignancies also remain at higher risk of mortality as well Nov 08, 2021
<乌鸦传媒>Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
<乌鸦传媒>FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
<乌鸦传媒>Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
<乌鸦传媒>Longer Hydroxyurea Tied to Improved Sickle-Cell Heart Issues Kids on treatment for less than 1 year had a significantly greater prevalence of LV dilation Sep 16, 2021
<乌鸦传媒>9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
<乌鸦传媒>Life Expectancy Still Lower for Blood or Marrow Transplant Recipients Although late mortality has decreased over the past 40 years Sep 09, 2021
<乌鸦传媒>Liver Toxicity in Gene Therapy Trials Could Merit Stricter Entry Criteria FDA panel weighs in on lower vector doses and role of animal studies Sep 03, 2021
<乌鸦传媒>Adding Mycophenolate Mofetil Improves Outcomes in ITP "Somewhat decreased" quality of life, however, British study finds Sep 01, 2021
<乌鸦传媒>Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphoma Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
<乌鸦传媒>Are Hemoglobin Cutoffs for Anemia Outdated? A growing call for WHO criteria to be tightened Aug 06, 2021
<乌鸦传媒>Woman Develops Tiny Blood Spots on Her Body After COVID Shot Case highlights need for quick diagnosis and management of rare disorder Aug 05, 2021
<乌鸦传媒>Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
<乌鸦传媒>Add-On Venetoclax Promising in Younger, Fit AML Patients "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
<乌鸦传媒>Call in the T-Cell Cavalry to Fight COVID in the Immunocompromised Preliminary research suggests immunotherapy could play role in protecting vaccine non-responders Jul 29, 2021
<乌鸦传媒>Shingrix OK'd for Immunocompromised Adults CDC's vaccine committee currently discussing vaccine for this population, manufacturer says Jul 26, 2021
<乌鸦传媒>Keytruda Before, After Surgery Improves Outcome in TNBC Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021
